Oscient Pharmaceuticals to Present at First Albany Capital Annual Growth Conference; Webcast of Presentation Available Tuesday, December 7, 2004 at 2:40 PM ET
Posted on: Tuesday, 30 November 2004, 18:00 CST
Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the First Albany Capital Annual Growth Conference on December 7, 2004 in New York City. The Company's President and CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the recent launch of FACTIVE(R) (gemifloxacin mesylate) tablets, the Company's lead product. The presentation will begin at 2:40 PM ET on Tuesday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 30 days.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for use in hospitalized patients.
The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium difficile-associated diarrhea (CDAD). The Company's preclinical program includes an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.
Source: Business Wire
Related Articles
- FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
- Oscient Pharmaceuticals' FACTIVE Tablets Subject of Poster Presentations at European Congress of Clinical Microbiology and Infectious Diseases; Leading European Conference Draws Key Scientific and Pharmaceutical Decision Makers
- Oscient Pharmaceuticals to Present Clinical Data on FACTIVE(R) Tablets at Chest 2005; Data Presentations Address Utility of FACTIVE in High-Risk Patients and Against Resistant Infections
- Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare Tailwinds Conference
- Oscient Pharmaceuticals to Present at Roth Capital Partners New York Conference
- Oscient Pharmaceuticals Achieves Primary Endpoint in Phase III Trial of FACTIVE Tablets for Potential Five-Day Treatment of Community-Acquired Pneumonia
- Oscient Pharmaceuticals Completes Enrollment in Pivotal Phase III Clinical Trial of FACTIVE Tablets for Potential Five-Day Treatment of Community-Acquired Pneumonia
- Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities Research Conference; Webcast of Presentation Available Wednesday, March 2, 2005 at 8:50 AM PT
- Oscient Pharmaceuticals to Present at JP Morgan Annual Healthcare Conference; Webcast of Presentation Available Monday, January 10, 2005 at 11:00 AM PT
 |
 |
User Comments (0)
RSS Feeds